SCHEMBL2368088

SCHEMBL2368088

Clc1cccc(-c2csc3ncn[c]c23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.45
PIP4K2C Q8TBX8 2/20 0.45
CYP19A1 P11511 1/20 0.38
DHFR P00374 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDR P35968 2/20 0.37
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.35
BRD4 O60885 1/20 0.35
NUDT1 P36639 2/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
CHEK1 O14757 1/20 0.35
FGFR1 P11362 2/20 0.35
PAX8 Q06710 1/20 0.35
DAPK3 O43293 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368766 0.83 MITF (0.44) HTTPIP4K2CMAPTKMT2ASMN1; SMN2
SCHEMBL2368956 0.82 HTT (0.55) HTTPIP4K2CMAPTKMT2ASMN1; SMN2
SCHEMBL2369061 0.82 FGFR1 (0.50) HTTSMN1; SMN2KDRFGFR1DAPK3
SCHEMBL2368453 0.80 PKM (0.51) HTTPIP4K2CCYP19A1MAPTSMN1; SMN2
SCHEMBL5790076 0.79 SMN1; SMN2 (0.37) HTTMAPTKMT2ASMN1; SMN2KDR
SCHEMBL2369510 0.74 SMN1; SMN2 (0.52) HTTPIP4K2CMAPTKMT2ASMN1; SMN2
SCHEMBL2369844 0.74 SMN1; SMN2 (0.52) HTTPIP4K2CMAPTKMT2ASMN1; SMN2
SCHEMBL4481360 0.72 KDR (0.69) HTTPIP4K2CDHFRMAPTKMT2A
SCHEMBL2368559 0.71 CHEK1 (0.43) HTTPIP4K2CMAPTKMT2ASMN1; SMN2
SCHEMBL2369522 0.70 MAPT (0.38) HTTMAPTKMT2ASMN1; SMN2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 HTT 543/4885PIP4K2C 2695/4885CYP19A1 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.